文献速递眼底病与葡萄膜炎

抗VEGF治疗糖尿病视网膜病变:非故意治疗中断的后果

Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions.
PubMed 文献 · Am J Ophthalmol · 2019-03-13

治疗中断中位时长12个月,随访时出现玻璃体出血、新生血管性青光眼和牵拉性视网膜脱离等并发症,77%的患眼视力下降≥3行,46%最终视力为手动或更差。

要点

  • 仅用抗VEGF治疗的糖尿病视网膜病变患者治疗中断可致疾病显著进展。
  • 中断中位12个月后,常见玻璃体出血、新生血管性青光眼和牵拉性视网膜脱离。
  • 77%患眼视力下降≥3行,46%最终视力为手动或更差。

核心结论

  • 仅接受抗VEGF治疗的糖尿病视网膜病变患者,非故意治疗中断可导致不可逆盲。

主要发现

  • 抗VEGF治疗指征为增殖性糖尿病视网膜病变(PDR)伴糖尿病黄斑水肿(DME)7眼(54%)、PDR不伴DME 3眼(23%)、中重度非增殖性糖尿病视网膜病变(NPDR)伴DME 3眼(23%)。
  • 治疗中断中位时长12个月,中断原因包括并发疾病(31%)、不依从(31%)和经济问题(15%)。
  • 随访并发症包括玻璃体出血9眼、新生血管性青光眼5眼、牵拉性视网膜脱离4眼。
  • 尽管治疗并发症,77%患眼视力下降≥3行,46%最终视力为手动或更差。

临床怎么用

  • 对仅用抗VEGF治疗的糖尿病视网膜病变患者,应特别关注治疗连续性,避免非故意中断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To illustrate that patients with diabetic retinopathy who are treated exclusively with anti-vascular endothelial growth factor (VEGF) therapy and have an interruption in treatment may experience marked progression of disease with potentially devastating visual consequences. DESIGN: Retrospective, multicenter, case series. METHODS: Retrospective review of patients treated exclusively with anti-VEGF therapy for proliferative diabetic retinopathy (PDR) or nonproliferative diabetic retinopathy (NPDR), with or without diabetic macular edema (DME), and temporarily lost to follow-up. Baseline disease characteristics, cause and duration of the treatment interruption, and resulting disease progression, complications, and outcomes were assessed. RESULTS: Thirteen eyes of 12 patients with type 2 diabetes were identified. The mean age was 57 ± 10 years, and 50% were women. Anti-VEGF therapy was indicated for PDR with DME in 7 (54%) eyes, PDR without DME in 3 (23%) eyes, and moderate to severe NPDR with DME in 3 (23%) eyes. Eight eyes had visual acuity (VA) of 20/80 or better before treatment interruption. The median duration of treatment hiatus was 12 months. Reasons for treatment interruption included intercurrent illness (31%), noncompliance (31%), and financial issues (15%). Complications upon follow-up included vitreous hemorrhage (9 eyes), neovascular glaucoma (5 eyes), and traction retinal detachment (4 eyes). Despite treatment of these complications, 77% of eyes lost ≥3 lines of VA, with 46% of eyes having a final VA of hand motion or worse. CONCLUSIONS: Diabetic patients are subject to significant lapses in follow-up because of illness, financial hardship, or noncompliance. In patients with diabetic retinopathy, especially PDR, who are managed with anti-VEGF therapy alone, unintentional treatment interruptions can result in irreversible blindness.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wubben TJ, Johnson MW. Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions. Am J Ophthalmol. 2019. PMID: 30878488. doi:10.1016/j.ajo.2019.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。